Skip to main content

Table 2 Quartile of baseline serum vitamin B12 levels with regard to host and viral factors and treatment response

From: Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study

Characteristics <340 (n = 27) 340–488 (n = 27) 488–727 (n = 26) >727 (n = 27) P value
Male sex n (%) 19 (70%) 20 (74%) 13 (50%) 13 (48%) 0.29
Age [median (range)] 47 (23–77) 53 (22–70) 51 (32–73) 51 (23–71) 0.74
HCV subtype n (%)
 1a 8 (29%) 12 (44%) 7 (27%) 6 (22%) 0.55
 1b 18 (67%) 15 (56%) 18 (69%) 19 (70%)
 1a + b 1 (4%) 0 1 (4%) 2 (8%)
RVR n (%) 19 (70%) 12 (44%) 9 (35%) 5 (19%) 0.001
SVR n (%) 22 (81%) 12 (44%) 7 (27%) 2 (7%) <0.001
AST [median (IQR)] U/L 39 (30–54) 42 (32–51) 45 (36–77) 73 (53–121) 0.002
ALT [median (IQR)] U/L 46 (24–94) 44 (27–64) 55 (36–85) 66 (49–150) 0.04
γ-GT [median (IQR)] U/L 38 (28–87) 52 (24–103) 63 (41–136) 68 (28–142) 0.12
Hepatitis activity n (%)
 Mild 21 (78%) 18 (67%) 19 (73%) 15 (56%) 0.58
 Moderate/severe 6 (22%) 9 (33%) 7 (27%) 12 (44%)
Fibrosis n (%)
 Absent/mild/moderate 26 (96%) 22 (81%) 22 (85%) 11 (41%) 0.0001
 Severe/cirrhosis 1 (4%) 5 (19%) 4 (15%) 16 (59%)
Steatosis
 0–5% 21 (78%) 19 (70%) 19 (73%) 15 (56%) 0.26
 6–100% 6 (22%) 7 (26%) 7 (27%) 12 (44%)
 Missing 0 1 (4%) 0 0
IFNL3/IFNL4 rs12979860 n (%)
 CC 16 (59%) 11 (41%) 5 (19%) 9 (33%) 0.04
 CT 8 (30%) 15 (55%) 15 (58%) 12 (44%) 8 (30%)
 TT 2 (7%) 1 (4%) 5 (19%) 5 (19%) 2 (7%)
 Missing 1 (4%) 0 1 (4%) 1 (4%) 1 (4%)
\